Kiora Pharmaceuticals GAAP EPS of -$0.54
Source: SeekingAlpha
2025-08-08 07:09:44 ET
More on Kiora Pharmaceuticals
- Kiora Pharmaceuticals granted U.S. patent expanding protection for KIO-104 for treatment of ocular disease
- Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals
- Historical earnings data for Kiora Pharmaceuticals
- Financial information for Kiora Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Kiora Pharmaceuticals GAAP EPS of -$0.54
Kiora Pharmaceuticals Inc.
NASDAQ: KPRX
KPRX Trading
2.75% G/L:
$2.055 Last:
20,490 Volume:
$1.96 Open:
KPRX Latest News
February 19, 2026 08:30:00 am
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
January 27, 2026 07:00:00 am
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
KPRX Stock Data
$8,275,354
3,558,312
6.34%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Encinitas
